Search results

Page results

• Immunomodulatory drug for COVID-19 trialled at UCLH

  UCLH is contributing to a national priority trial of the drug ruxolitinib in patients with Covid-19 pneumonia (infection of the lungs).

• Staff and patients delighted with the newly refurbished Neurorehabilitation Unit

  The Neurorehabilitation Unit (NRU) at The National Hospital for Neurology and Neurosurgery (NHNN) has been refurbished with funding from The National Brain Appeal to provide new facilities and additional space, transforming it into a more therapeutic environment.

• Penile plication (Nesbit) procedure

  Penile plication (Nesbit) procedure post-operative information

• UCLH recruits first patient globally for new Alzheimer’s Disease trial

  UCLH has recruited the first patient to a global study of a new drug in early development, called NI0752, which is thought to reduce the production of a protein in the brain called tau.

• Steroid treatment for inflammation caused by immunotherapy

  This information is for patients receiving steroids for immunotherapy toxicity.

• Cancer immunotherapy treatment

  This page is for patients receiving steroids for immunotherapy toxicity.

• One year at the Royal National ENT and Eastman Dental Hospitals

  The hospital marked the start of the year a visit by HM The Queen in February 2020. A few weeks after this celebration, the pandemic took hold and the hospital stepped up to help.

• Research into restoring loss of smell and taste in COVID patients

  Specialist teams at UCLH and UCL are at the forefront of research which could bring hope to people who have been robbed of their sense of smell and taste after suffering the long-term legacy of COVID-19.

• Study reveals limitations of drug proposed for lung cancer treatment

  Researchers at UCLH and UCL have completed the first and only randomised trial to explore a new approach to treating aggressive lung cancer.

• World-first CJD treatment shows promising early results

  A world-first treatment for Creutzfeldt-Jakob disease (CJD) has shown “very encouraging” early results following its use in six patients at University College London Hospitals (UCLH) NHS Foundation Trust.